Literature DB >> 27015757

Physiological functions and pathobiology of TDP-43 and FUS/TLS proteins.

Antonia Ratti1,2, Emanuele Buratti3.   

Abstract

The multiple roles played by RNA binding proteins in neurodegeneration have become apparent following the discovery of TAR DNA binding protein 43 kDa (TDP-43) and fused in sarcoma/translocated in liposarcoma (FUS/TLS) involvement in amyotrophic lateral sclerosis and frontotemporal lobar dementia. In these two diseases, the majority of patients display the presence of aggregated forms of one of these proteins in their brains. The study of their functional properties currently represents a very promising target for developing the effective therapeutic options that are still lacking. This aim, however, must be preceded by an accurate evaluation of TDP-43 and FUS/TLS biological functions, both in physiological and disease conditions. Recent findings have uncovered several aspects of RNA metabolism that can be affected by misregulation of these two proteins. Progress has also been made in starting to understand how the aggregation of these proteins occurs and spreads from cell to cell. The aim of this review will be to provide a general overview of TDP-43 and FUS/TLS proteins and to highlight their physiological functions. At present, the emerging picture is that TDP-43 and FUS/TLS control several aspects of an mRNA's life, but they can also participate in DNA repair processes and in non-coding RNA metabolism. Although their regulatory activities are similar, they regulate mainly distinct RNA targets and show different pathogenetic mechanisms in amyotrophic lateral sclerosis/frontotemporal lobar dementia diseases. The identification of key events in these processes represents today the best chance of finding targetable options for therapeutic approaches that might actually make a difference at the clinical level. The two major RNA Binding Proteins involved in Amyotrophic Lateral Sclerosisi and Frontotemporal Dementia are TDP-43 and FUST/TLS. Both proteins are involved in regulating all aspects of RNA and RNA life cycle within neurons, from transcription, processing, and transport/stability to the formation of cytoplasmic and nuclear stress granules. For this reason, the aberrant aggregation of these factors during disease can impair multiple RNA metabolic pathways and eventually lead to neuronal death/inactivation. The purpose of this review is to provide an up-to-date perspective on what we know about this issue at the molecular level. This article is part of the Frontotemporal Dementia special issue.
© 2016 International Society for Neurochemistry.

Entities:  

Keywords:  ALS; FTLD; FUS/TLS; RNA binding proteins; TDP-43; protein aggregation

Mesh:

Substances:

Year:  2016        PMID: 27015757     DOI: 10.1111/jnc.13625

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  133 in total

1.  Heavy Metal Neurotoxicants Induce ALS-Linked TDP-43 Pathology.

Authors:  Peter E A Ash; Uma Dhawan; Samantha Boudeau; Shuwen Lei; Yari Carlomagno; Mark Knobel; Louloua F A Al Mohanna; Steven R Boomhower; M Christopher Newland; David H Sherr; Benjamin Wolozin
Journal:  Toxicol Sci       Date:  2019-01-01       Impact factor: 4.849

2.  Dysregulation of TDP-43 intracellular localization and early onset ALS are associated with a TARDBP S375G variant.

Authors:  Kathy Newell; Francesca Paron; Miguel Mompean; Jill Murrell; Elisa Salis; Cristiana Stuani; Gary Pattee; Maurizio Romano; Douglas Laurents; Bernardino Ghetti; Emanuele Buratti
Journal:  Brain Pathol       Date:  2018-12-27       Impact factor: 6.508

3.  Neuron-to-Neuron Transfer of FUS in Drosophila Primary Neuronal Culture Is Enhanced by ALS-Associated Mutations.

Authors:  Sébastien Feuillette; Morgane Delarue; Gaëtan Riou; Anne-Lise Gaffuri; Jane Wu; Zsolt Lenkei; Olivier Boyer; Thierry Frébourg; Dominique Campion; Magalie Lecourtois
Journal:  J Mol Neurosci       Date:  2017-04-20       Impact factor: 3.444

Review 4.  From animal models to human disease: a genetic approach for personalized medicine in ALS.

Authors:  Vincent Picher-Martel; Paul N Valdmanis; Peter V Gould; Jean-Pierre Julien; Nicolas Dupré
Journal:  Acta Neuropathol Commun       Date:  2016-07-11       Impact factor: 7.801

5.  The minor spliceosome could be the major key for FUS/TLS mutants in ALS.

Authors:  Emanuele Buratti
Journal:  EMBO J       Date:  2016-06-10       Impact factor: 11.598

Review 6.  Cajal bodies in neurons.

Authors:  Miguel Lafarga; Olga Tapia; Ana M Romero; Maria T Berciano
Journal:  RNA Biol       Date:  2016-09-14       Impact factor: 4.652

Review 7.  Liquid-Liquid Phase Separation and Its Mechanistic Role in Pathological Protein Aggregation.

Authors:  W Michael Babinchak; Witold K Surewicz
Journal:  J Mol Biol       Date:  2020-03-10       Impact factor: 5.469

8.  TDP-43 and Tau Oligomers in Alzheimer's Disease, Amyotrophic Lateral Sclerosis, and Frontotemporal Dementia.

Authors:  Mauro Montalbano; Salome McAllen; Filippa Lo Cascio; Urmi Sengupta; Stephanie Garcia; Nemil Bhatt; Anna Ellsworth; Eric A Heidelman; Omar D Johnson; Samantha Doskocil; Rakez Kayed
Journal:  Neurobiol Dis       Date:  2020-10-14       Impact factor: 5.996

9.  Quantification of the Relative Contributions of Loss-of-function and Gain-of-function Mechanisms in TAR DNA-binding Protein 43 (TDP-43) Proteinopathies.

Authors:  Roberta Cascella; Claudia Capitini; Giulia Fani; Christopher M Dobson; Cristina Cecchi; Fabrizio Chiti
Journal:  J Biol Chem       Date:  2016-07-21       Impact factor: 5.157

Review 10.  SMN regulation in SMA and in response to stress: new paradigms and therapeutic possibilities.

Authors:  Catherine E Dominguez; David Cunningham; Dawn S Chandler
Journal:  Hum Genet       Date:  2017-08-29       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.